403
Sorry!!
Error! We're sorry, but the page you were
looking for doesn't exist.
Briacell Therapeutics Corp
(MENAFN- Baystreet) 09:54 AM EST - BriaCell Therapeutics Corp : Announces that the external Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor the safety data of the BriaCell clinical study to determine if the study should continue, be modified, or be halted, has completed its second safety data review of BriaCell's pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in metastatic breast cancer and recommended continuation of the ongoing study without any modifications. BriaCell Therapeutics Corp
shares T are trading up $0.31 at $6.45.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Comments
No comment